IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Cytokines play important roles in tumorigenesis and progression of cancer cells, while their functions in drug resistance remain to be illustrated. We successfully generated doxorubicin (Dox)-resistant CRC HCT-116 and SW480 cells (namely HCT-116/Dox and SW480/Dox, respectively). Cytokine expression analysis revealed that IL-8, while not FGF-2, EGF, TGF-β, IL-6, or IL-10, was significantly increased in Dox-resistant CRC cells as compared with their corresponding parental cells. Targeted inhibition of IL-8 via siRNAs or its inhibitor reparixin can increase the Dox sensitivity of HCT-116/Dox and SW480/Dox cells. The si-IL-8 can decrease the mRNA and protein expression of multidrug resistance 1 (MDR1, encoded by ABCB1), while has no effect on the expression of multidrug resistance-associated protein 1 (ABCC1), in CRC Dox-resistant cells. IL-8 can increase the phosphorylation of p65 and then upregulate the binding between p65 and promoter of ABCB1. BAY 11-7082, the inhibitor of NF-κB, suppressed the recombination IL-8 (rIL-8) induced upregulation of ABCB1. It confirmed that NF-κB is involved in IL-8-induced upregulation of ABCB1. rIL-8 also increased the phosphorylation of IKK-β, which can further activate NF-κB, while specific inhibitor of IKK-β (ACHP) can reverse rIL-8-induced phosphorylation of p65 and upregulation of MDR1. These results suggested that IL-8 regulates the Dox resistance of CRC cells via modulation of MDR1 through IKK-β/p65 signals. The targeted inhibition of IL-8 might be an important potential approach to overcome the clinical Dox resistance in CRC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, P-gp is overexpressed in CRC cell lines and specimens resistant to 5-FU/Dox/oxaliplatin [31,117,118].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [118]
Citations
Cites
1 retracted
Xi, G., Hayes, E., Lewis, R., Ichi, S., Mania-Farnell, B. L., Shim, K., Takao, T., Allender, E., Mayanil, C. S. K., & Tomita, T. (2015) · Oncogene · doi:10.1038/onc.2015.78 · Cited by 67
RetractedMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
De Larco, J. E., Wuertz, B. R. K., & Furcht, L. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0760 · Cited by 412
Ning, Y., Manegold, P. C., Hong, Y. K., Zhang, W., Pohl, A., Lurje, G., Winder, T., Yang, D., LaBonte, M. J., Wilson, P. M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25562 · Cited by 406
Transcriptional regulation of ABC drug transporters
Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 392
Benoy, I. H., Salgado, R., Van Dam, P., Geboers, K., Van Marck, E., Scharpé, S., Vermeulen, P. B., & Dirix, L. Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0812 · Cited by 356
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
A global view on cancer incidence and national levels of the human development index
Fidler, M. M., Soerjomataram, I., & Bray, F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30382 · Cited by 334
The NF-κB/IκB signaling system: A molecular target in breast cancer therapy
Wu, J. T., & Kral, J. G. (2005) · Journal of Surgical Research · doi:10.1016/j.jss.2004.06.006 · Cited by 205
Sui, H. X., Fan, Z.-Z., & Li, Q. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000204 · Cited by 171
Yu, M., Ocaña, A., & Tannock, I. F. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9402-8 · Cited by 163
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer
Lurje, G., Zhang, W., Schultheis, A. M., Yang, D., Groshen, S. G., Hendifar, A. E., Husain, H., Gordon, M. A., Nagashima, F., Chang, H.-M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn368 · Cited by 135
Shi, Z., Yang, W., Chen, L., Yang, D., Zhou, Q., Zhu, J., Chen, J.-J., Huang, R., Chen, Z., & Huang, R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2196-0 · Cited by 122
Wang, Y., Qu, Y., Niu, X. L., Sun, W. J., Zhang, X. L., & Li, L. Z. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.005 · Cited by 122
Orditura, M., Vita, F. D., Catalano, G., Infusino, S., Lieto, E., Martinelli, E., Morgillo, F., Castellano, P., Pignatelli, C., & Galizia, G. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900260442557 · Cited by 84
Qu, J., Zhao, L., Zhang, P., Wang, J., Xu, N., Mi, W., Jiang, X., Zhang, C., & Qu, J. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24366 · Cited by 84
Wu, Y.-M., Chen, Z.-J., Liu, H., Wei, W.-D., Lu, L.-L., Yang, X., Liang, W.-T., Liu, T., Liu, H.-L., Du, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4436 · Cited by 65
Self-citationTruncated APC regulates the transcriptional activity of β-catenin in a cell cycle dependent manner
Schneikert, J., Grohmann, A., & Behrens, J. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl464 · Cited by 62
Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells
Niiya, M., Niiya, K., Kiguchi, T., Shibakura, M., Asaumi, N., Shinagawa, K., Ishimaru, F., Kiura, K., Ikeda, K., Ueoka, H., et al. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0665-1 · Cited by 54
Colombo, V., Lupi, M., Falcetta, F., Forestieri, D., D’Incalci, M., & Ubezio, P. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1335-8 · Cited by 54
APC selectively mediates response to chemotherapeutic agents in breast cancer
VanKlompenberg, M. K., Bedalov, C. O., Soto, K. F., & Prosperi, J. R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1456-x · Cited by 45
Shao, N., Chen, L., Ye, R.-Y., Lin, Y., & Wang, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.022 · Cited by 43
Park, S., Han, J., Kim, J. B., Yang, M.-G., Kim, Y. J., Lim, H., An, S. Y., & Kim, J. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.021 · Cited by 43
Min, J., Liu, L., Li, X., Jiang, J., Wang, J., Zhang, B., Cao, D., Yu, D., Tao, D., Hu, J., et al. (2015) · Scientific Reports · doi:10.1038/srep16578 · Cited by 40
Zhang, Z., Wang, Y., Xu, S., Yu, Y., Hussain, A., Shen, Y., & Guo, S. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01253e · Cited by 32
Rial, N. S., Lazennec, G., Prasad, A. R., Krouse, R. S., Lance, P., & Gerner, E. W. (2009) · International Journal of Cancer · doi:10.1002/ijc.24226 · Cited by 30
APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation
VanKlompenberg, M. K., Leyden, E., Arnason, A., Zhang, J., Stefanski, C. D., & Prosperi, J. R. (2017) · Oncotarget · doi:10.18632/oncotarget.22263 · Cited by 24
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?
Liptrott, N. J., & Owen, A. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.553600 · Cited by 21
CXCR2 inhibition enhances sulindac‐mediated suppression of colon cancer development
Lee, Y. S., Choi, D., Kim, N. Y., Yang, S. H.-Y., Jung, E., Hong, M., Yang, D., Lenz, H., & Hong, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28668 · Cited by 14
Cited by
Fousek, K., Horn, L. A., & Palena, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107692 · Cited by 359
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)
Tian, Y., Lei, Y., Wang, Y., Lai, J., Wang, J., & Xia, F. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5567 · Cited by 197
“Notably, NF‐κB (P65) may be activated by IL‐8 via upregulation of IKKβ phosphorylation, thus resulting in over‐ expression of P‐gp (49).”
BackgroundThe Role of Interleukins in Colorectal Cancer
Li, J., Huang, L., Zhao, H., Yan, Y., & Lü, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.46651 · Cited by 162
“IL-8 participates in most phases of tumour development from cell proliferation and angiogenesis to cancer metastasis, moreover, some evidence has shown that IL-8 is associated with chemotherapeutic responses [91-93].”
BackgroundDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Self-citation
Metadata
- Authors
- Du, J., He, Y., Li, P., Wu, W., Chen, Y., & Ruan, H.
- Affiliations
- Zhejiang Provincial People's Hospital (CN)
- Nanchang University (CN)
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2018-04-24
- Volume
- 81
- Issue
- 6
- Pages
- 1111-1119
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2799985672
- Cited by
- 52
- References
- 34
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 5 · 2023: 14 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 3 · 2018: 2
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- the Natural Science Foundation of Zhejiang Province (LQ17H160016)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- interleukin-8, doxorubicin resistance, colorectal cancer, multidrug resistance 1, P-glycoprotein, NF-κB signaling, IKKβ, p65 phosphorylation, cytokines, reparixin, chemoresistance
- MeSH terms
- Antibiotics, Antineoplastic, Doxorubicin, Humans, Nitriles, Phosphorylation, Sulfonamides, Sulfones, Colorectal Neoplasms, Up-Regulation, Gene Expression Regulation, Neoplastic, Cytokines, Interleukin-8, NF-kappa B, ATP Binding Cassette Transporter, Subfamily B, Drug Resistance, Neoplasm, RNA, Small Interfering, HCT116 Cells, Cell Line, Tumor, I-kappa B Kinase, Transcription Factor RelA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.